4D Molecular Therapeutics Q2 Net Income USD -72.936 Million Vs. IBES Estimate USD -70.3 Million
FDMT•Q2 earnings and revenue figures
Aug. 13 (Reuters) - 4D Molecular Therapeutics Q2 operating expenses were USD 80.806 million.
- Q2 operating income was USD -77.025 million vs. IBES estimate USD -74.3 million
- Q2 basic EPS was USD -1.04
- Q2 revenue was USD 3.781 million vs. IBES estimate USD 3.1 million
